Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? - Itzykson, R.; Thépot, S.; Beyne-Rauzy, O.; Ame, S.; Isnard, F.; Dreyfus, F.; Salanoubat, C.; Taksin, A.L.; Chelgoum, Y.; Berthon, C.; Malfuson, J.V.; Legros, L.; et al. (Leukemia Research, 2012)